摘要
目的探讨bufalin-mPEG-PLGA-PLL-cRGD体内药物靶向分布规律,为大肠癌的临床治疗提供实验依据和方法。方法建立荷C26结肠癌裸鼠模型,并随机分为两组:Dir-bufalin-mPEG-PLGA-PLL纳米组和Dir-bufalin-mPEG-PLGA-PLL-cRGD纳米组,经尾静脉给药。药物注射后3、19h后采用活体成像系统测定裸鼠活体的荧光强度。结果注射纳米粒3、19h后,与Dir-bufalin-mPEG-PLGA-PLL纳米粒相比,注Dir-bufalin-mPEG-PLGA-PLL-cRGD纳米粒的荷瘤裸鼠肿瘤部位显示出较高的荧光强度。结论 Dir-bufalin-mPEG-PLGA-PLL-cRGD纳米粒能更有效地靶向大肠癌。本实验制备的载药纳米粒的体内荧光活体成像实验数据表明,该纳米粒有助于提高大肠癌的治疗效果。
Objective To investigate the in vivo targeting efficacy of nanoparticles （ NPs ） made of methoxy polyethylene glycol （ mPEG）, polylactic - co - glycolic acid （ PLGA）, poly - 1 - lysine （ PLL）, and cyclic arginine - glycine - aspartic acid （cRGD） loaded with bufalin （bufalin -mPEG -PLGA -PLL -cRGD NPs） , and to provide experimental evidence and method for the application of bufa- lin to treat colon cancer. Methods The mice were classified into 2 groups on the basis of the nanoparticles that they were administered： Dir - bufalin - mPEG - PLGA - PLL - cRGD NPs group and Dir - bufalin - of mPEG - of PLGA - PLL - cRGD NPs group, by injection through the vena caudalis one time in the experience. Fluorescence imaging of the tumor bearing mice was performed at 3 and 19h after in- jection by using a small animal in vivo fluorescence imaging system. Results Compared with the Dir - bufalin - mPEG - PLGA - PLL nanoparticles, the tumor fluorescence intensity of the mice treated with Dir - mPEG - PLGA - PLL - cRGD NPs was relatively stronger and lasted longer at 3h and 19h post - injection. Conclusion The Dir - bufalin - mPEG - PLGA - PLL - cRGD nanoparticles resulted in better tumor targeting and longer residue time in vivo. The experimental data show that the nanoparticles can help to improve the treatment effect of colorectal cancer.
出处
《医学研究杂志》
2013年第7期54-57,共4页
Journal of Medical Research
基金
国家自然科学基金青年科学基金资助项目(81001594)
上海市自然科学基金资助项目(11ZR1433200)
上海市科委纳米专项基金资助项目(11nm0504500)
上海市卫生局中医处基金资助项目(2010QL050B)
上海市科委引导基金资助项目(114119B3100)
上海市普陀区科委创新重大项目(2011PTKW001)
关键词
蟾毒灵
纳米
cRGD
大肠肿瘤
肿瘤靶向
Bufalin
Nanoparticles
Cyclic arginine - glycine - aspartic acid （cRGD）
Colon cancer
Tumor targetet
